Recursion's AI-designed cancer drugs REC-3565 and REC-617 show early clinical promise, with one patient responding unexpectedly well to treatment.

Recursion Pharmaceuticals grew its share prices for a fourth straight day on Monday, adding 9.59 percent to close at $6.40 apiece as investors repositioned portfolios ahead of its second quarter ...

 An overview of attention detection using EEG signals, which includes six steps: an experimental paradigm design, in which the task and the stimuli are defined and presented to the subjects ...

Check out our RXRX stock chart to see a history of performance, current stock value, and a timeline of financial events & indicators for a full analysis today.